Business
PRTC Publishes Previous LYT-100 MAD Study Results
PRTC Publishes Previous LYT-100 MAD Study Results.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4601S\n PureTech Health PLC\n 16 November 2021\n \n \n \n 16 November 2021\n \n PureTech Health plc\n \n \n \n \n \n PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates\n \n \n \n \n \n LYT-100 well-tolerated at all doses studied with a favorable PK profile; maximum tolerated dose not determined; additional studies underway to evaluate higher doses.\n \n \n \n \n \n \n Phase 2 enrollment of LYT-100 in patients with \n \n \n Long COVID1\n \n \n respiratory complications expected to complete by year-end; results anticipated in 1H 2022.\n \n \n \n \n \n \n \n Phase 1 healthy volunteer trials underway to further evaluate LYT-100 PK, dosing and tolerability to inform clinical development of LYT-100 across multiple indications; results anticipated in \n \n \n Q1 \n \n \n 2022. \n \n \n \n \n \n \n \n \n PureTech Health plc \n \n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a\n clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that the results from a Phase 1 trial evaluating multiple ascending doses and the food effect of LYT-100 (deupirfenidone) were published in the journal \n \n \n Clinical Pharmacology in Drug Development\n \n \n . Topline results from this Phase 1 study were previously \n \n \n announced\n \n \n \n in November 2020 and demonstrated that LYT-100 was well-tolerated in healthy volunteers under both fed and fasting conditions. \n \n \n \n \n \n LYT-100 is PureTech's wholly-owned therapeutic candidate that is being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow. It is currently being evaluated in two Phase 2 trials in patients with Long COVID respiratory complications and breast cancer-related, upper limb secondary lymphedema. Enrollment in the Long COVID respiratory trial is expected to be completed by the end of 2021, with topline results anticipated in the first half of 2022. Topline results from the breast cancer-related, upper limb secondary lymphedema trial are anticipated in 2022. \n \n \n \n \n \n \"The data set from...